Medical cannabis is not a standard treatment for Tourette’s syndrome or tic disorders in UK guidance. Some research has looked at cannabis-based medicines for adults with Tourette’s, and some results look promising, but the evidence is still not strong enough for broad claims or routine use.
A Tourette’s or tic disorder diagnosis does not automatically mean someone may qualify for medical cannabis. A specialist would need to look at tic severity, previous treatment history, age, mental health, ADHD, OCD, anxiety, medicine interactions, substance-use risk, driving, work, education and safeguarding.
This guide is for UK patients, families and carers preparing for a realistic conversation. It is not medical advice, it is not a recommendation to use cannabis for tics, and it does not replace a neurologist, psychiatrist, GP, pharmacist or specialist prescriber. For general access context, see MCPH’s medical cannabis qualifying conditions guide and how the UK medical cannabis prescription process works.
The short answer
Tourette’s syndrome can cause sudden movements and sounds called tics. Tics can be mild for some people and very disruptive for others. They often start in childhood and can change over time.
Medical cannabis may be discussed in a specialist assessment for a small number of patients with severe, treatment-resistant symptoms, but it should not be sold as a simple tic treatment. NICE cannabis-based medicinal products guidance does not recommend medical cannabis for Tourette’s or tic disorders. NHS information on Tourette’s focuses on education, behavioural therapy, medicines where needed, and support for coexisting conditions.
A 2024 systematic review and meta-analysis of cannabis-based medicine in Tourette syndrome reported reductions in tic severity scores in the included adult studies, but the authors still called for larger placebo-controlled studies. That matters. A research signal is not the same as a reliable patient promise.
Evidence: what can and cannot be said
The strongest safe wording is that the evidence is developing but limited. Some adult studies have reported tic-score changes after cannabis-based medicine. The studies vary in design, product type, outcome measures and follow-up. Children and young people are especially sensitive because long-term safety, development and mental-health risks need more care.
This article should not say cannabis treats Tourette’s. It should not say THC or CBD controls tics. It should not suggest a patient should try non-prescribed cannabis to test suitability. It should not recommend a product, dose, route, strain, clinic or pharmacy.
The practical question is narrower: could a specialist justify a monitored cannabis-based medicinal product for this patient after standard options have been considered, risks have been screened, and goals have been agreed? The answer may be no.
ADHD, OCD, anxiety and mental-health overlap
Tourette’s and tic disorders often sit alongside other conditions. NHS information recognises that some people with Tourette’s may also have ADHD, obsessive compulsive disorder, anxiety or other difficulties. That overlap is central to a medical cannabis assessment.
The prescriber needs to understand whether the main problem is tics, premonitory urges, anxiety, sleep, obsessive thoughts, attention, impulsivity, mood, pain, social distress or another issue. These should not be blurred into one cannabis question.
Mental-health screening should cover:
- anxiety, panic, depression and suicidal thoughts
- OCD symptoms and intrusive thoughts
- ADHD symptoms, stimulant or non-stimulant medicines
- psychosis, paranoia, bipolar disorder or mania history
- self-harm, substance-use concerns and non-prescribed cannabis use
- previous adverse reactions to cannabis, CBD, alcohol or sedating medicines
RCPsych warns that cannabis can affect mental health, and THC-containing products can be a concern for people vulnerable to psychosis, anxiety or dependence. That does not mean every patient with tics is unsuitable. It means the screening has to be honest and specialist-led.
Previous treatment history and records
A clinic will usually want to see what has already been tried and what happened. For tic disorders, that may include education and practical support, behavioural approaches, treatment for ADHD or OCD, mental-health care, medicines for tics, school or workplace adjustments, and specialist neurology or psychiatry input.
The Summary Care Record from the GP surgery is often the practical starting point because it may show current medicines, recent medicines, coded diagnoses and allergies. If the SCR does not show enough detail, the clinic may ask for neurology letters, psychiatry letters, child and adolescent mental-health notes, school reports, assessment letters or medicine history.
This is a records step, not a request to persuade a GP to prescribe medical cannabis. Suitability, product choice, route, dose and monitoring sit with the specialist prescriber.
Children, young people and safeguarding
Tourette’s often begins in childhood, so age matters. A medical cannabis discussion for a child or young person needs a higher safety bar than an adult discussion. The clinician must consider development, education, consent, family responsibilities, mental health, safeguarding, substance exposure and whether other support has been properly tried.
For under-18s, a parent or guardian may be involved, but the young person’s voice still matters where they can take part. For adults who need support with decisions, capacity and consent should be handled carefully and lawfully. Carers can help describe patterns and risk, but they should not turn distress into a treatment demand that overrides the patient’s own experience.
If tics are causing injury, severe distress, school exclusion, work problems or family strain, that deserves serious care. It still does not make cannabis automatically suitable.
Interactions, impairment and daily life
Many patients with tic disorders may also take medicines for ADHD, anxiety, depression, OCD, sleep, pain or other conditions. NHS medical cannabis guidance says CBD and THC can affect how other medicines work. The clinician and pharmacist need the full list before any decision.
Patients should be open about:
- prescribed medicines
- over-the-counter medicines and supplements
- CBD products
- alcohol and non-prescribed cannabis use
- stimulant medicines, sedatives or antipsychotics
- previous side effects such as panic, paranoia, sleepiness or confusion
Impairment also matters. Medical cannabis can affect alertness, coordination, reaction time and judgement. The UK drug-driving rules apply, and nobody should drive while impaired. Work, education, caring roles, machinery and sports drug testing may also need discussion.
Questions to ask a clinic
Useful questions include:
- What evidence do you use when assessing Tourette’s or tics and medical cannabis?
- Are you assessing tics, premonitory urges, anxiety, sleep, OCD, ADHD or another issue?
- Which previous treatments or supports do you need to see in my records?
- How will you screen for anxiety, OCD, ADHD, psychosis, substance-use risk and previous cannabis reactions?
- How would we measure tic severity, side effects and impairment?
- What would make you decide not to prescribe, pause, or stop treatment?
- How are consent, safeguarding and carer involvement handled?
- What are the driving, work, education or drug-testing implications?
The aim is not to push the clinician towards a prescription. It is to make sure the assessment is clinically grounded and honest about risk.
What this article is not saying
This article is not saying medical cannabis treats Tourette’s syndrome or tic disorders. It is not saying cannabis reliably reduces tics. It is not saying diagnosis equals eligibility. It is not recommending CBD, THC, flower, oil, extracts, a strain, a clinic, a pharmacy, a dose or a route.
It is saying that Tourette’s and tic disorders may be discussed in a specialist assessment for some UK patients, but the evidence is still developing and the safety checks are important. ADHD, OCD, anxiety, mental-health history, substance-use risk, age, consent, interactions and impairment should shape the decision.
Sources
- NHS: Medical cannabis
- NHS: Tourette’s syndrome
- NHS: Attention deficit hyperactivity disorder
- NICE: Cannabis-based medicinal products, NG144
- NHS England: Cannabis-based products for medicinal use
- GMC: Information for doctors on cannabis-based products for medicinal use
- CQC: Cannabis-based medicinal products: what CQC expects from providers
- RCPsych: Cannabis and mental health
- GOV.UK: Drug driving law
- PubMed: Efficacy of cannabis-based medicine in the treatment of Tourette syndrome: a systematic review and meta-analysis
